Nebulizers

2025: Reduction of nebulizer sales in Russia by 7.4% to ₽4,61 billion

Retail sales of nebulizers in Russia in 2025 amounted to ₽4,61 billion. The market volume in physical terms reached 2.09 million units. The data on February 4, 2026 is provided by the analytical company RNC Pharma.

Compared to 2024, consumer cash spending on inhalers decreased by 7.4%. Physical demand decreased by 5.2%. The decline in sales was recorded for the first time in several years both in traditional retail and in the online segment.

Marketplaces for the first time exceeded half of all natural sales of nebulizers. In three years, the share of Internet sites has more than doubled. The pharmacy segment lost 22 percentage points over the same period. The share of the FMCG channel has almost tripled.

In 2025, online sales of inhalers decreased by 1% in pieces. Pharmacy retail lost 9% of its physical volume. In previous years, the Internet channel showed double-digit growth rates.

The average cost of the device on marketplaces decreased over three years by more than ₽800 and amounted to about ₽1,5 thousand per unit. In pharmacies, the price rose to ₽2,9 thousand - the increase was only ₽60.

Compressor models occupy 70% of the natural market volume and 86% of the cost. Their share is gradually decreasing. Ultrasonic instruments such as MES have become the only growing segment. Natural consumption of MES nebulizers increased by 14%, cash costs - by 11%. The share of this type of device reached 26%.

Unbranded models occupy more than 24% of the natural volume of the market. In value terms, they account for 7.4%. The leader in cash sales is the Japanese Omron with a share of 28%. Swiss "Bi.Vell" occupies 22% of the market. Japan's "Hey End Dee" closes the top three with 17%.^[1]

2024: Russian market growth 3.4% to ₽5 billion

According to the analytical company RNC Pharma, the Russian retail market for nebulizers, including online sales, exceeded ₽5 billion in 2024. In physical terms, sales grew by 15% to 2.2 million devices, with a cash increase of 3.4%. This became known in February 2025.

According to RNC Pharma, the nebulizer market demonstrates pronounced seasonality with sales peaks during periods of growth in respiratory diseases. During 2024, the following dynamics were observed:

• Maximum in January - 287 thousand devices for ₽702 million.
• At least in July - 84.6 thousand devices for ₽196 million.
• Autumn peak in October - 263.7 thousand devices for ₽554 million.
• Decrease in December by 27.5% compared to December 2023.

According to the Smorodintsev Research Institute of Influenza, the dynamics of sales directly correlates with the incidence of ARVI and influenza. At the end of 2023 and the beginning of 2024, a high incidence rate was observed, which led to a peak in sales in December 2023 - 328 thousand devices worth ₽814 million.

The structure of the nebulizer market in Russia in 2024 is as follows:

• Omron (Japan) - 28.5% of the market in monetary terms, the leader of the segment.
• B.Well (Switzerland) - 22% of the market, a stable second position.
• A&D (Japan) - 16% of the market, closes the top three.
• Unbranded devices - 26% in physical terms and 10% in monetary terms.

Analysts note a strong relationship between nebulizer and drug sales for obstructive airway diseases. Two drugs dominate this category: Pulmicort from AstraZeneca and Berodual from Boehringer Ingelheim, which jointly occupy 92% of the market in physical terms and 95% in monetary terms.

Sales of inhalation drugs also show seasonal fluctuations. The maximum sales volume of Pulmicort was recorded in December 2023 at ₽818 million, but by December 2024 the figure had decreased to ₽585 million. Similar dynamics was observed with the drug "Berodual": the peak of sales in December 2023 amounted to ₽230 million, and in October 2024 - ₽184 million.^[2]

2023: Sales growth in Russia by 0.5% to 4.9 billion rubles

At the end of 2023, sales of nebulizers (devices for inhalation with ultra-small dispersed spraying of a drug substance) in Russia amounted to 4.9 billion rubles in monetary terms. This is 0.5% more than the result for the previous year. At the same time, in physical terms, sales rose by 9.6%. Such figures are given in a study by the analytical company RNC Pharma, the results of which were published on February 2, 2024.

It is said that in 2023 the market developed primarily due to the e-commerce segment, which provided monetary dynamics at the level of 40.4%. In physical terms, sales in this sector increased by 67.6% compared to 2022. At the same time, offline sales in 2023 decreased by 10.3% in monetary terms and by 9.5% in kind.

𝓲

Фото: RNC Pharma

The Russian market as a whole (including online channels) mainly sells compressor-type nebulizers: in 2023 they provided 89% of sales in monetary terms and 86% in kind. At the same time, this type of devices is gradually replaced by ultrasonic products, which in 2023 occupied about 10% in money and 15% in pieces.

The study says that in Russia there are geographical differences in terms of assortment and pricing policy in the nebulizer market. The most expensive devices are sold in the Far East, where the devices cost an average of 3.16 thousand rubles. The second place is taken by the Central Federal District with an indicator of 2.98 thousand rubles, and the North Caucasus closes the top three with a figure of 2.92 thousand rubles. The cheapest devices are sold in the Southern Federal District, where the cost of inhalers is on average 2.66 thousand rubles. It is noted that network marketplaces exert serious pressure on the market in all federal districts, except for the Far East.^[3]

Notes